Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2011

Open Access 01-09-2011 | Article

Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets

Authors: D. Favre, G. Niederhauser, D. Fahmi, V. Plaisance, S. Brajkovic, N. Beeler, F. Allagnat, J. A. Haefliger, R. Regazzi, G. Waeber, A. Abderrahmani

Published in: Diabetologia | Issue 9/2011

Login to get access

Abstract

Aims/hypothesis

Pro-atherogenic and pro-oxidant, oxidised LDL trigger adverse effects on pancreatic beta cells, possibly contributing to diabetes progression. Because oxidised LDL diminish the expression of genes regulated by the inducible cAMP early repressor (ICER), we investigated the involvement of this transcription factor and of oxidative stress in beta cell failure elicited by oxidised LDL.

Methods

Isolated human and rat islets, and insulin-secreting cells were cultured with human native or oxidised LDL or with hydrogen peroxide. The expression of genes was determined by quantitative real-time PCR and western blotting. Insulin secretion was monitored by EIA kit. Cell apoptosis was determined by scoring cells displaying pycnotic nuclei.

Results

Exposure of beta cell lines and islets to oxidised LDL, but not to native LDL raised the abundance of ICER. Induction of this repressor by the modified LDL compromised the expression of important beta cell genes, including insulin and anti-apoptotic islet brain 1, as well as of genes coding for key components of the secretory machinery. This led to hampering of insulin production and secretion, and of cell survival. Silencing of this transcription factor by RNA interference restored the expression of its target genes and alleviated beta cell dysfunction and death triggered by oxidised LDL. Induction of ICER was stimulated by oxidative stress, whereas antioxidant treatment with N-acetylcysteine or HDL prevented the rise of ICER elicited by oxidised LDL and restored beta cell functions.

Conclusions/interpretation

Induction of ICER links oxidative stress to beta cell failure caused by oxidised LDL and can be effectively abrogated by antioxidant treatment.
Appendix
Available only for authorised users
Literature
1.
Donath MY, Ehses JA, Maedler K et al (2005) Mechanisms of β-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113PubMedCrossRef
2.
Brunham LR, Kruit JK, Verchere CB, Hayden MR (2008) Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118:403–408PubMedCrossRef
3.
Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW (2007) Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56:2328–2338PubMedCrossRef
4.
Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF (2000) Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 49:399–408PubMedCrossRef
5.
Poitout V, Robertson RP (2002) Minireview: secondary beta-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339–342PubMedCrossRef
6.
Okajima F, Kurihara M, Ono C, Nakajima Y et al (2005) Oxidized but not acetylated low-density lipoprotein reduces preproinsulin mRNA expression and secretion of insulin from HIT-T15 cells. Biochim Biophys Acta 1687:173–180PubMed
7.
Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915–924PubMedCrossRef
8.
Ruderman NB, Haudenschild C (1984) Diabetes as an atherogenic factor. Prog Cardiovasc Dis 26:373–412PubMedCrossRef
9.
Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749PubMedCrossRef
10.
Nakhjavani M, Khalilzadeh O, Khajeali L et al (2010) Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 45:321–327PubMedCrossRef
11.
Cullen P, von Eckardstein A, Souris S, Schulte H, Assmann G (1999) Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1:189–198PubMedCrossRef
12.
Rohrer L, Hersberger M, von Eckardstein A (2004) High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269–278PubMedCrossRef
13.
Abderrahmani A, Niederhauser G, Favre D et al (2007) Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 50:1304–1314PubMedCrossRef
14.
Brewer HB Jr (2004) High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 24:387–391PubMedCrossRef
15.
Drew BG, Duffy SJ, Formosa MF et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119:2103–2111PubMedCrossRef
16.
Rutti S, Ehses JA, Sibler RA et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150:4521–4530PubMedCrossRef
17.
Maziere C, Morliere P, Santus R et al (2004) Inhibition of insulin signaling by oxidized low density lipoprotein. Protective effect of the antioxidant Vitamin E. Atherosclerosis 175:23–30PubMedCrossRef
18.
Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381–1478PubMedCrossRef
19.
Tardif JC, McMurray JJ, Klug E et al (2008) Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371:1761–1768PubMedCrossRef
20.
Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Matsuhisa M, Yamasaki Y (2005) Oxidative stress and the JNK pathway in diabetes. Curr Diabetes Rev 1:65–72PubMedCrossRef
21.
Kaneto H, Matsuoka TA, Katakami N et al (2007) Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 7:674–686PubMedCrossRef
22.
Beeler N, Riederer BM, Waeber G, Abderrahmani A (2009) Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. Brain Res Bull 80:274–281PubMedCrossRef
23.
Ferdaoussi M, Abdelli S, Yang JY et al (2008) Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 57:1205–1215PubMedCrossRef
24.
Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P (1993) Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75:875–886PubMedCrossRef
25.
Abderrahmani A, Cheviet S, Ferdaoussi M, Coppola T, Waeber G, Regazzi R (2006) ICER induced by hyperglycemia represses the expression of genes essential for insulin exocytosis. EMBO J 25:977–986PubMedCrossRef
26.
Zhou YP, Marlen K, Palma JF et al (2003) Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? J Biol Chem 278:51316–51323PubMedCrossRef
27.
Inada A, Hamamoto Y, Tsuura Y et al (2004) Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells. Mol Cell Biol 24:2831–2841PubMedCrossRef
28.
Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81:3883–3887PubMedCrossRef
29.
Cnop M, Hannaert JC, Grupping AY, Pipeleers DG (2002) Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143:3449–3453PubMedCrossRef
30.
Scheidegger KJ, Cenni B, Picard D, Delafontaine P (2000) Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective effects. J Biol Chem 275:38921–38928PubMedCrossRef
31.
Laoide BM, Foulkes NS, Schlotter F, Sassone-Corsi P (1993) The functional versatility of CREM is determined by its modular structure. EMBO J 12:1179–1191PubMed
32.
Thiel G, Lietz M, Hohl M (2004) How mammalian transcriptional repressors work. Eur J Biochem 271:2855–2862PubMedCrossRef
33.
Iezzi M, Escher G, Meda P et al (1999) Subcellular distribution and function of Rab3A, B, C, and D isoforms in insulin-secreting cells. Mol Endocrinol 13:202–212PubMedCrossRef
34.
Abderrahmani A, Niederhauser G, Plaisance V et al (2004) Complexin I regulates glucose-induced secretion in pancreatic β-cells. J Cell Sci 117:2239–2247PubMedCrossRef
35.
Wolff SP, Dean RT (1987) Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes. Biochem J 245:243–250PubMed
36.
Berliner JA, Territo MC, Sevanian A et al (1990) Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85:1260–1266PubMedCrossRef
37.
Henriksen T, Mahoney EM, Steinberg D (1981) Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 78:6499–6503PubMedCrossRef
38.
Kajimoto Y, Kaneto H (2004) Role of oxidative stress in pancreatic beta-cell dysfunction. Ann NY Acad Sci 1011:168–176PubMedCrossRef
39.
Rabinovitch A, Suarez-Pinzon WL, Strynadka K, Lakey JR, Rajotte RV (1996) Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production. J Clin Endocrinol Metab 81:3197–3202PubMedCrossRef
40.
Robbesyn F, Garcia V, Auge N et al (2003) HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 17:743–745PubMed
41.
Abderrahmani A, Plaisance V, Lovis P, Regazzi R (2006) Mechanisms controlling the expression of the components of the exocytotic apparatus under physiological and pathological conditions. Biochem Soc Trans 34:696–700PubMedCrossRef
42.
Inada A, Someya Y, Yamada Y et al (1999) The cyclic AMP response element modulator family regulates the insulin gene transcription by interacting with transcription factor IID. J Biol Chem 274:21095–21103PubMedCrossRef
43.
Nakhjavani M, Morteza A, Meysamie A et al (2010) Serum heat shock protein 70 and oxidized LDL in patients with type 2 diabetes: does sex matter? Cell Stress Chaperones 2:195–201
44.
Robertson RP (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279:42351–42354PubMedCrossRef
45.
Nakhjavani M, Asgharani F, Khalilzadeh O et al (2010) Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus. Am J Med Sci 2:92–95
46.
Kaneto H, Kajimoto Y, Miyagawa J et al (1999) Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 48:2398–2406PubMedCrossRef
47.
Paolisso G, D’Amore A, Galzerano D et al (1993) Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 16:1433–1437PubMedCrossRef
48.
Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272PubMedCrossRef
49.
Gorogawa S, Kajimoto Y, Umayahara Y et al (2002) Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract 57:1–10PubMedCrossRef
50.
Millea PJ (2009) N-acetylcysteine: multiple clinical applications. Am Fam Physician 80:265–269PubMed
Metadata
Title
Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets
Authors
D. Favre
G. Niederhauser
D. Fahmi
V. Plaisance
S. Brajkovic
N. Beeler
F. Allagnat
J. A. Haefliger
R. Regazzi
G. Waeber
A. Abderrahmani
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2165-x

Other articles of this Issue 9/2011

Diabetologia 9/2011 Go to the issue

Commentary

Type 2 diabetes: unravelling the interaction between genetic predisposition and lifestyle

For Debate

The threshold hypothesis: solving the equation of nurture vs nature in type 1 diabetes

Article

Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans

Article

Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes

Article

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

Retraction Note

Erratum to: Retraction of ‘Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats’

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits